It's been a pretty wild ride for Alnylam (Nasdaq:ALNY) shareholders, even by the elevated standards of biotechnology. Once thought to have the IP keys to one of the next great platform technologies (RNA interference), the stock was hammered down over several years as multiple Big Pharma companies chose to back away from the technology and partnerships with Alnylam. Since late 2011, though, it's been a return to investor love for Alnylam as positive clinical data and a bull market in biotech has fueled a fourfold rise in the shares.

Discount Brokers Comparison: Your one-stop shop for finding the perfect broker for your investments.

5x15 Means Multiple Shots On Goal
Alnylam has largely guided itself according to its “5 x 15” program, which is a focused and prioritized list of development candidates designed to have five products in clinical trials by 2015. While there are many promising targets for RNA interference (RNAi), Alnylam has chosen to focus its time and resources on largely orphan genetic diseases. There are not all that many people in the world with familial amyloid polyneuropathy, intermittent porphyria, or familial amyloidotic cardiomyopathy, but other biotechs like Alexion (Nasdaq:ALXN) and BioMarin (Nasdaq:BMRN) have amply demonstrated that there is a very worthwhile commercial markets in rare diseases with no effective treatment options.

Farthest along in the proprietary pipeline are two drugs for amyloidosis – TTR02 for familial amyloid polyneuropathy (FAP) and TTRsc for familial amyloidotic cardiomyopathy (FAC). TTR02 has shown encouraging early-stage results, but Phase II data (likely to be presented at the end of June) will be critical for the program and the stock. Likewise, while TTRsc is even earlier in development (currently in Phase 1 testing), data in mid-2013 is likely to garner significant attention.

Beyond this, the company has preclinical candidates for hemophilia (ALN-AT3) and intermittent porphyria (ALN-AS1) that it intends to get into clinical testing over the next 12 months. Other compounds for hemophilia and blood disorders like thalassemia and antitrypsin deficiency are also in preclinical testing, with the company ideally hoping to partner some of these prior to initiating Phase 1 testing.

Alnylam also has a candidate in the race for the next blockbuster cholesterol drug. ALN-PCS is a PCSK9 inhibitor, a class of drugs that has garnered significant attention from the investment community and drug companies like Amgen (Nasdaq:AMGN) and Sanofi (NYSE:SNY). Although Alnylam's Phase I data was encouraging, the company chose to partner the drug out to The Medicines Company (Nasdaq:MDCO) for further development, making it apparent that smaller scale orphan drug development is the company's preferred strategy for now.

SEE: Investing In The Healthcare Sector

Orphans Getting Plenty Of Love Recently
In stark contrast to the implications of the name, orphan drugs have actually been getting a great deal more popular with investors and drug companies recently. As mentioned before, companies like Alexion and BioMarin (not to mention Sanofi's Genzyme) have found great commercial success with their orphan drug development programs.

Although these markets are, by definition, not large (typically fewer than 50,000 patients worldwide, and often fewer than 5,000), the diseases in question tend to be extremely serious (life or death) and with no effective current therapies. That combination has helped support eye-popping price tags for these drugs, often north of $200,000 a year.

But it's not just the prospect of lucrative reimbursement and various government-sponsored barriers to entry that make these markets appealing. As the patient populations are small, the trials tend to be small as well, which makes them cheaper to run and faster to enroll. What's more, the lack of therapeutic options often allows for drug developers to run relatively short trials where efficacy is established fairly quickly. Although the FDA still insists on clinical efficacy and acceptable efficacy/safety tradeoffs (as Pfizer (NYSE:PFE) learned when the FDA rejected its application for Vyndaqel in FAP), overall these drug development cycles are faster and cheaper.

SEE: Earning Forcasts: A Primer

The Bottom Line
It is extremely early in the Alnylam story, and I frankly find all of the enthusiasm over Phase I results to be at least in part a symptom of the biotech bull market. That said, the company's IP is impressive and the preclinical and (very) early-stage clinical data from the company have been compelling. While I hate talking about “The next...” in reference to biotechs, the reality is that this company may be the next Regeneron (Nasdaq:REGN), Amgen, or Gilead (Nasdaq:GILD).

When valuing early-stage biotechs, a huge amount of guess work goes into the process. What's more, it's worth noting that somewhere between 85% and 90% of prospective new drugs ultimately fail. That said, I believe that TTR02 and TTRsc combined could be worth more than $28 per share today to Alnylam investors (with $1 billion in potential revenue for each drug, even with potential competition from a partnership of Isis (Nasdaq:ISIS) and Glaxo (NYSE:GSK)). With the same arguably being true for drugs for anemia, hemophilia, porphyria, and other blood disorders (to say nothing of licensing potential in other diseases), a price target of around $30 is not unreasonable today.

I do own these shares myself and I do believe in the potential of RNA interference as a platform technology in biotech/pharmaceuticals. That said, investors considering these shares today need to be aware of the very high risk involved – Alnylam is very early-stage, Big Pharma support for RNA interference has been inconsistent at best, and we are about three years into a strong biotech bull market. Still, for those investors shopping around for a potential platform company in biotech, Alnylam may be a name worth considering.

At the time of writing, Stephen D. Simpson owned shares of Alnylam.

Related Articles
  1. Trading Strategies

    Riding The Momentum Investing Wave

    Buy high and sell higher. Find out if you could surf these risky waters.
  2. Options & Futures

    Rules For Post-Recession Investing

    Market volatility causes investors to lose confidence, yet history shows that market exposure is the path to returns.
  3. Fundamental Analysis

    Investing Basics: Flight To Quality

    At times of market stress, investors flee from risky assets to investments the safest ones available.
  4. Personal Finance

    Zika Virus: Latest Advice on Staying Safe

    Zika has hit the U.S. Here’s the most recent update on what’s known about the virus, how it spreads, who’s at highest risk and how to avoid it.
  5. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  6. Stock Analysis

    Hologic: An Activist Investment Analysis (HOLX)

    Read about a health care company that attracted activist investors Carl Icahn, Barry Rosenstein and Ralph Whitworth at the same time.
  7. Investing

    How To Make Sure Your Healthcare Costs Do Not Ruin Your Retirement

    The best proactive plan of action for a stable retirement is to understand medical costs, plan ahead, invest properly, and consider supplemental insurance.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Stock Analysis

    Moderna Therapeutics: An IPO Candidate in 2016?

    Find out the reasons why 2016 may be the year when highly valued biotech company Moderna Therapeutic files for an initial public offering (IPO).
  10. Investing News

    Stryker Corporation: A Strong Capital Position

    A discussion on business operations, financials, valuation and growth trends for Stryker Corporation.
RELATED FAQS
  1. What is Fibonacci retracement, and where do the ratios that are used come from?

    Fibonacci retracement is a very popular tool among technical traders and is based on the key numbers identified by mathematician ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center